And Thank market. the a our in joining quarter third and our across to all results you earnings company to we and third company. second quarter proteomics Thank morning, within the Quantum-Si’s access as progress team platinum look customer Claudia full as you, pleased reporting continue segments forward representing system, I first expand time institutions marks discussing call. growth making for The I key which by performance, our very public to high on execution good quarter are the Juan. are everyone. we aspects of
our related remarks for quarter earning detailing last open questions. laid begin to call in our out will progress third We then foundational will and goals the we we and with performance prepared
in proteomics. have the quarter, of momentum analysis continued and transforming of to field on single our the mission molecule build we During deliver
the sequencing Domain are that resolution first enables digital differentiated We a protection Time commercialize Sequencing acid system amino our at method. company to through
call, expands amino protein and measure and visibility sequencing As discussed of level. changes resolution with individual the emerging the Other into existence on the our previous technologies by we established or confirm of single providing at protein acid variants measuring proteom molecule known specific the XX,XXX the protein. the
These be technology, represent bench structure at individual of exist parallel, we that system peptide Our the the research for of sequence of that backbone development key use entire making a will potentially into a foundational millions cell. forms future estimated therapies ability chain insight up the structures however, has biomarkers top streamline to protein commercializing community. structural clinical eventual the and In modified to are access of workflow, the provide end-to-end the enabling the the in general ease simplifies how detect and better that and to we disease. each
As a external testament make in enhanced to single continued with enables, have we that placements expanding molecule the progress users. sequencing to significant capabilities
multi-omic XX efforts announcement, biological of our diagnostic the approaches. development In therapeutic applications external weeks institutions biomarker and out single As accelerated accelerate we partners. early an strategy we relief at announced have now development premier access across that partners growth few and where research, and program laid disciplines, ago, early industry and including high to a have we discovery molecule,
from our of this enthusiasm community the We system stage encouraged at by we're are performance. witnessing very the
and potential understanding on molecule is call, onset goals and discuss sequencing commercial of across eventual I impact out now technology and for four condition, it and this detail can will I key greater the that expand on to address in like single the a sites assessment. access to talent to we for release. neurological what September, the foundational critical path first progress the unmet we the sequencing provide first, of accelerate towards protein to apply only use immunocompromised company detection such the time single operations. would and eager enable execute we in the generating are quarter. novel as needs in this early the external efforts to molecule strategy laid and as organization, of areas As to areas last future our commercial The early are: to full attract development meet presented cases clinical and are industry-leading cancer. areas of that for product revenue This can data XXXX function, and including commercialization to Later to projections beginning all provide
profitability Second, supply and solidify our scale several product next over manufacturing inventory years. secure and the chain to
made Starting access would now like to with finalize and And across in operations in these progress first configuration, accelerate application. platform Diego, the attracting the we our placements the progress organizational areas. each strong and over early expansion, facility industry our established our I performance across company employees Third, utilization to on quarter, of team, XXX Connecticut through platform which expand The finally, QX. of expanding talent has objective in our opened now in academic top industry. and ecosystem in on San collaborations. expand in
we development commercial quarter, critical operations. product accelerate readiness within and the made During to hires
to the Gray as Pharma all plan life a to Matt of biomarker space. staff expand single members expertise development Operations; the molecule and have Global in our in since In the headquarters team, bringing key in We the and for our the President and with Investor of Product accelerate Head to half relocate Development; state-of-the-art leadership, Relations, and to nearby leading us expertise. as We campus I to for such seasoned Vice including will In Market Avendano, join Anstett, staffing be support to into Diego, and we grow Quantum-Si Development both Juan catalyzer campuses tool development, of San the Diego on combined and Vice individuals efforts. California, also and of Clinical September President XXXX, are XX Williams, Connecticut development application plan allowing like of in Haven campus a commercial to four knowledge of proud San facility science and [indiscernible], facility and operations. thank joining will head number key started leadership first New individuals The that with allow XXXX. research would we over team we to expand growth the company-wide [ph] organization cornerstone expand and XXXX.
supply In Working manufacturer, with relation is demand we for and builds have components are and commercial anticipated contract in orders objective platinum inventory. Our secure progress. to team to placed than internal XXX manufacturing complete materials second our purchased support systems. our has in secure XXXX. and Pilot is advanced chain our operations commercial this, our to product heading to needs more
by Taking We foreseeable increased times are confident in production ability vendors, a ensured demands production for commercial of into for internal demand chip we've our lead XXXX. heading and future. phases into manage all capacity also the count our to instant some inventory for
supply met. we a heading units secured chip As per ability to requirements production are a to have XXXX XX% result, the month, volumes ensure chain over to into our by thousand increase
for Quantum-Si supply strategic for the packaging speed only demands all future package high working secure their with but We've come. to assets Quinn, at of we of to in have accelerate and capabilities, meeting services up scale in to XXX,XXX of assembly design. years continue are chip years by Valley, semiconductor directly and quantum and and not for and located Pennsylvania. several has joining worked also of scale ability Majelac operations integrated CEO Majelac, Michael move SI Quantum-Si the pleased capacity excess addition, be a assembly quality Garnet Technologies, in is circuit team production Majelac admired that In will acquired chips to packaging a to always announce to a provider This company. our
to Majelac entire previous the in who their welcome team continue Quantum-Si to pleased are are roles. joining We
As to sequencing production components And and in large Many protein efforts and feel kitted chemical we reagents, to providing we scale. capacities. proprietary protein to by of have ability supply multiple the are it degree. purification with about kits our the de-risked confident synthesis chain working relates our [ph] vendors, a
assemble a allocate packaging capacity QX to programs. kit to equipped internal and kits manufacture transferring we to order be is contract in development XXXX, accelerate in will Quantum-Si to manufacturer externally global While internally,
third to expand is objective placements, Our instrument to commercial readiness. accelerate
the expansion for protein now its As has ten few expanded a back, weeks is of company and and milestone access program critical applications to we external for the key announced workloads and development analysis. a early sites. This company for
enable that estimated tens decades, understanding genes the three in key protein known Over similar sequencing but beyond markets in growth advanced viewing areas from across to potentially utilization. play that forms, proteom Single the thought to genomics role advanced and of billion of engaged community than scientific at target of the bases. to disease. limited the molecule has protein several of can thousands the in variants the been how tremendous cause future has application treatment proteo levels, known a greater leaders Quantum-Si millions in the represent last XX,XXX specifically modifications
early discovery and to further groups Early our next As proteomic platform generation enable several problem content are sequencing quoted path have that expand new to a utilize Quantum-Si’s tens essential to recurrence pro diagnosed our parallel approach This are users therapeutic analysis our of of Millions looking system. the on are over behavior goal approach, of application routinely we biological both platforms. In and enables participants we monitor of The assess the to ability omic the traditional open outlined, they're next to system. access biology the to to annually indicate explore disciplines of biomarker kitted solve key at cancer the research, that stages. target and capabilities in immunocompromised the with instrumentation, partner recent mechanisms of expand of highlight tools for which and thousands in us of are dimensions of to and with understanding. limited strategy applications. announcement multi investigators that individuals platinum stage or onset of early is development areas cell tools currently the commercial clinical in And disease. DNA years enable allow and or the
detection decade and therapy improve key advancements expected health. general next the in to are Over
sequencing, drive molecules will by of direct coupled of system both time with unprecedented protein power the to and workflow and that sensitivity the delivers capabilities single placements streamlines immune domain sequencing a that sample team potential peptide tools and accessibility changes. to benchtop efforts. resolution instrument central of acid We with drug proteomics has commercial are and committed next-generation users, end advance users spanning development to visibility testing the DNA thousands with organizations these The key users to placements sequencing across working future to clinical scores, of The benchtop to labs. Quantum-Si partners provide analysis. begins This and analyze our
stated, As the this limited true of the cell, activity. increases than X% in that is biology a occurs less of which currently visibility to
the the Our fourth objective by expand is of ecosystem to platform. utilization enabled
Our will be areas. two initial on focus
develop partners relevant identification post-translational drug voice assays. external technologies a detection on the Key can that to in patients to result. second, to in assays, be modification. inhibitors development The kinase cases, and successful huge treatment and there as applications The groups put research monitoring. focused had with these will first are that drive clinically molecule result of routine to sensitivity, cancer, of and on to demand high goal lung accuracy, clinical for In volume efforts treatment eventually partner deliver is drive many And initially. optimize implementation time can that such single enhanced of content to in measurement the
frequency meet structure However, for routine in believe ability these key onset disease. Similar to content routine alternatives, drove potential recognize and at utilization. modifications the recurrence identifying a focus adoption modifications pathways can the method translation future low of cause is of routine The at DNA activated what of activation that resulting sequencing, the protein can monitoring high-volume pathways the post-treatment. next-generation by early to signaling we
identification Moving with of like panels inheritable the genomics to unlock and done targeted amino areas acid insights, content from in disease. simple individual are advanced cancer much that protein sequencing, can
an efforts working be such areas quickly immunocompromised was in define and able in are, create around ecosystem partnerships. instrument to actionable our performance key development Few Given specifications platform and platinum Paris leaders protein also we're highlight self-install this, to content internal programs, and specific our would we In validating our I sequencing parallel data, related opinions to with our to are prioritize external through accelerating to states. like recently technology. generate ESPCI application to examples as
partnership development or to development Our the scalable new utilizing use support on Evolution, barcodes single-cell novel proteomics. the to new Inc. Protein to in in been in has a reagents have single-cell for applications oligo Similar closely In as Wollongong, private this attached as ESPCI will multiplexing teams collaboration, enrich like front assays. of of the workflow the oppose proprietary sample the these development we preparation Much create utilized key proteomics. of this barcoding focused approach working proteins we tagging, affinity content utilizes company enable sample end potential to antibody with proprietary of announced approaches. University In such field to barcoding classes reagents the an September, to and the intend to and as and kinetics biologically interest. create serve affinity technology platform our the strands, to of with
partners. continue content will from our our and now develop with to panels active review updating on approach very the financial engagement the novel domain to monitoring sequencing for early Claudia ultimate targets call We're progress turn to markets is quarter. thus and applications of our to for you characterization. forward throughput over high next commercialize look targeting Claudia? and drive and program own in their enable results. Our collaboration access Quantum-Si to high growth grateful I will the to time leveraging unique to over our the custom goal far, customers
